Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2007

Compendia Bioscience Signs Oncomine Licensing Agreement with AstraZeneca

  • Compendia Bioscience licensed Oncomine™, the company’s compendium of oncology gene expression profiles and analysis tools, to AstraZeneca. The firm will conduct a year-long pilot to evaluate the long-term role of this product in its cancer research programs.

    This licensing agreement gives AstraZeneca access to Oncomine Concepts Edition (OCM), a value-added product extension of Oncomine that reportedly combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »